These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 1345984)

  • 1. Recombinant factor VIII concentrate. The MSAC, Canadian Hemophilia Society. Canadian Hemophilia Clinic Directors Group.
    Walker I; Poon MC
    Lancet; 1992 Jan; 339(8784):61-2. PubMed ID: 1345984
    [No Abstract]   [Full Text] [Related]  

  • 2. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant factor VIII in hemophilia A: the Canadian experience.
    Blanchette VS
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S33-9. PubMed ID: 9351535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A.
    Hsu HC; Chen YF; Ho CH
    Zhonghua Yi Xue Za Zhi (Taipei); 1999 Jul; 62(7):450-4. PubMed ID: 10418180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Recombinant factor VIII concentrate].
    Fukutake K
    Rinsho Byori; 1992 Mar; Suppl 92():94-106. PubMed ID: 1583781
    [No Abstract]   [Full Text] [Related]  

  • 6. Factor concentrate prophylaxis for neonates with hemophilia.
    Buchanan GR
    J Pediatr Hematol Oncol; 1999; 21(4):254-6. PubMed ID: 10445886
    [No Abstract]   [Full Text] [Related]  

  • 7. Hepatitis C infection in patients with hemophilia: results of a national survey. Canadian Hemophilia Clinic Directors Group.
    Blanchette V; Walker I; Gill P; Adams M; Roberts R; Inwood M
    Transfus Med Rev; 1994 Jul; 8(3):210-7. PubMed ID: 8081082
    [No Abstract]   [Full Text] [Related]  

  • 8. Recombinant factor VIII in hemophilia.
    Cohen A; Butler R
    N Engl J Med; 1991 May; 324(21):1515-6. PubMed ID: 1902552
    [No Abstract]   [Full Text] [Related]  

  • 9. Recombinant factor VIII: an introduction.
    Büchel KH
    Semin Hematol; 1991 Apr; 28(2 Suppl 1):1-4. PubMed ID: 1908119
    [No Abstract]   [Full Text] [Related]  

  • 10. [Cryoprecipitate should have preference over factor VIII concentrate in the treatment of patients with hemophilia A].
    Kunst VA; Nováková IR; Haanen C
    Ned Tijdschr Geneeskd; 1989 Jun; 133(23):1163-6. PubMed ID: 2501689
    [No Abstract]   [Full Text] [Related]  

  • 11. Laboratory and clinical markers of HIV infection in a national haemophilia cohort treated with recombinant factor VIII concentrate. The Association of Hemophilia Clinic Directors of Canada.
    Teitel JM; Card R; Strawczynski H
    Haemophilia; 1998 Sep; 4(5):731-8. PubMed ID: 9873879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant factor VIII: are we really getting more for less?
    Gorlin JB; Ewenstein BM
    J Pediatr; 1997 Apr; 130(4):507-9. PubMed ID: 9108841
    [No Abstract]   [Full Text] [Related]  

  • 13. Surveillance for factor VIII inhibitor development in the Canadian Hemophilia A population following the widespread introduction of recombinant factor VIII replacement therapy.
    Giles AR; Rivard GE; Teitel J; Walker I
    Transfus Sci; 1998 Jun; 19(2):139-48. PubMed ID: 10187039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of using safer blood products on prevalence of HIV infection in haemophilic Canadians. Canadian Hemophilia Clinic Directors Group.
    BMJ; 1993 Jan; 306(6873):306-7. PubMed ID: 8461649
    [No Abstract]   [Full Text] [Related]  

  • 15. The current status of recombinant human factor VIII.
    Aronson DL
    Semin Hematol; 1991 Apr; 28(2 Suppl 1):55-6. PubMed ID: 1908131
    [No Abstract]   [Full Text] [Related]  

  • 16. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group.
    Lusher JM; Arkin S; Abildgaard CF; Schwartz RS
    N Engl J Med; 1993 Feb; 328(7):453-9. PubMed ID: 8421474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design of clinical studies with recombinant factor VIII. The rFactor VIII Clinical Trial Group.
    Pennington JE; Schwartz RS
    Semin Hematol; 1991 Apr; 28(2 Suppl 1):27-8. PubMed ID: 1908123
    [No Abstract]   [Full Text] [Related]  

  • 18. A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the haemophilia A population of Canada. Association of Hemophilia Centre Directors of Canada. Factor VIII/IX Subcommittee of Scientific and Standardization Committee of International Society on Thrombosis and Haemostasis.
    Giles AR; Verbruggen B; Rivard GE; Teitel J; Walker I
    Thromb Haemost; 1998 Apr; 79(4):872-5. PubMed ID: 9569207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Developing rDNA products for treatment of hemophilia A.
    Kaufman RJ
    Trends Biotechnol; 1991 Oct; 9(10):353-9. PubMed ID: 1367761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. recombinant Factor VIII Study Group.
    Schwartz RS; Abildgaard CF; Aledort LM; Arkin S; Bloom AL; Brackmann HH; Brettler DB; Fukui H; Hilgartner MW; Inwood MJ
    N Engl J Med; 1990 Dec; 323(26):1800-5. PubMed ID: 2123300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.